These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 31521192

  • 21. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM, Marchesoni A, Lubrano E.
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P, Husni ME, Kafka S, Chakravarty SD, Harrison DD, Lo KH, Xu S, Hsia EC, Kavanaugh A.
    Arthritis Res Ther; 2020 Mar 06; 22(1):43. PubMed ID: 32143685
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis.
    Appani SK, Devarasetti PK, Irlapati RVP, Rajasekhar L.
    Rheumatology (Oxford); 2019 May 01; 58(5):869-873. PubMed ID: 30590763
    [Abstract] [Full Text] [Related]

  • 25. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter Borg EJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG.
    Lancet; 2016 Jul 23; 388(10042):343-355. PubMed ID: 27287832
    [Abstract] [Full Text] [Related]

  • 26. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
    Weinblatt ME, Bingham CO, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R.
    Ann Rheum Dis; 2013 Mar 23; 72(3):381-9. PubMed ID: 22661646
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial.
    Edwards CJ, Östör AJK, Naisbett-Groet B, Kiely P.
    Rheumatology (Oxford); 2018 Jan 01; 57(1):84-91. PubMed ID: 29155973
    [Abstract] [Full Text] [Related]

  • 29. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT.
    Arthritis Rheum; 2006 Jan 01; 54(1):26-37. PubMed ID: 16385520
    [Abstract] [Full Text] [Related]

  • 30. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P.
    Arthritis Rheum; 2010 Apr 01; 62(4):917-28. PubMed ID: 20131276
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S.
    J Rheumatol; 2016 Jul 01; 43(7):1268-77. PubMed ID: 27252426
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.
    Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Mann H, Santos MJ, Reino JG, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, van der Horst-Bruinsma IE, Macfarlane GJ, Iannone F, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML.
    Rheumatology (Oxford); 2020 Jul 01; 59(7):1640-1650. PubMed ID: 31665497
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC, Saurigny D, Vencovsky J, Takeuchi T, Nakamura T, Matsievskaia G, Hunt B, Wagner T, Souberbielle B, NEXUS Study Group.
    Arthritis Res Ther; 2019 Apr 18; 21(1):101. PubMed ID: 30999929
    [Abstract] [Full Text] [Related]

  • 36. Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.
    Emamikia S, Arkema EV, Györi N, Detert J, Chatzidionysiou K, Dougados M, Burmester GR, van Vollenhoven R.
    RMD Open; 2016 Apr 18; 2(2):e000323. PubMed ID: 27651929
    [Abstract] [Full Text] [Related]

  • 37. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.
    Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O'Keeffe AG, Maddison PJ, Scott DL.
    Rheumatology (Oxford); 2012 Aug 18; 51(8):1368-77. PubMed ID: 22344575
    [Abstract] [Full Text] [Related]

  • 38. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.
    Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ.
    J Rheumatol; 2019 May 18; 46(5):475-482. PubMed ID: 30647182
    [Abstract] [Full Text] [Related]

  • 39. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
    Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G.
    Ann Rheum Dis; 2014 Jun 18; 73(6):1020-6. PubMed ID: 24595547
    [Abstract] [Full Text] [Related]

  • 40. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.
    Clin Ther; 2003 Jun 18; 25(6):1700-21. PubMed ID: 12860493
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.